Robert Mohapatra, MD, MPH
NPI: 1336311661
Total Payments
$162,137
2024 Payments
$12,532
Companies
36
Transactions
1,077
Medicare Patients
11,700
Medicare Billing
$780,609
Payment Breakdown by Category
Other$117,708 (72.6%)
Food & Beverage$16,963 (10.5%)
Consulting$15,625 (9.6%)
Travel$11,785 (7.3%)
Education$55.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $117,708 | 57 | 72.6% |
| Food and Beverage | $16,963 | 956 | 10.5% |
| Consulting Fee | $15,625 | 9 | 9.6% |
| Travel and Lodging | $11,785 | 52 | 7.3% |
| Education | $55.85 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $57,343 | 166 | $0 (2024) |
| Relypsa, Inc. | $51,667 | 77 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $22,740 | 245 | $0 (2024) |
| Lilly USA, LLC | $9,913 | 12 | $0 (2024) |
| Amgen Inc. | $5,957 | 105 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $3,760 | 29 | $0 (2024) |
| Esperion Therapeutics, Inc. | $2,240 | 30 | $0 (2024) |
| Medtronic Vascular, Inc. | $1,492 | 12 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $1,069 | 93 | $0 (2024) |
| Abbott Laboratories | $981.56 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,532 | 114 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,988) |
| 2023 | $9,767 | 54 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,590) |
| 2022 | $13,523 | 100 | Boehringer Ingelheim Pharmaceuticals, Inc. ($10,346) |
| 2021 | $8,306 | 123 | Boehringer Ingelheim Pharmaceuticals, Inc. ($3,864) |
| 2020 | $6,685 | 87 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,049) |
| 2019 | $28,425 | 209 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,271) |
| 2018 | $37,451 | 192 | Relypsa, Inc. ($21,965) |
| 2017 | $45,447 | 198 | Relypsa, Inc. ($29,684) |
All Payment Transactions
1,077 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Abbott Laboratories | NAVITOR (Device) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: Vascular | ||||||
| 12/20/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.50 | General |
| Category: Cardiovascular | ||||||
| 12/06/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $17.67 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/22/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Cardiology | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $4.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: DIABETES | ||||||
| 11/20/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Genetic Disease | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.44 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/28/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $50.22 | General |
| Category: Cardiovascular Device | ||||||
| 10/25/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $10.00 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/15/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Cardiology | ||||||
| 10/01/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $10.15 | General |
| Category: Cardiovascular | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $8.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: DIABETES | ||||||
| 09/27/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $122.56 | General |
| Category: Heart Failure | ||||||
| 09/20/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Genetic Disease | ||||||
| 09/19/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/13/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 3,208 | 4,069 | $613,550 | $194,606 |
| 2022 | 16 | 2,841 | 3,745 | $614,037 | $198,848 |
| 2021 | 21 | 2,902 | 3,784 | $626,679 | $210,788 |
| 2020 | 27 | 2,749 | 3,513 | $499,277 | $176,366 |
Total Patients
11,700
Total Services
15,111
Medicare Billing
$780,609
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 431 | 700 | $198,800 | $67,410 | 33.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 160 | 337 | $80,653 | $33,966 | 42.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 208 | 211 | $90,730 | $30,537 | 33.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 158 | 200 | $33,015 | $13,229 | 40.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 189 | 189 | $44,604 | $10,409 | 23.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 169 | 178 | $42,008 | $9,261 | 22.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 1,022 | 1,229 | $30,725 | $8,063 | 26.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 408 | 561 | $30,855 | $6,399 | 20.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $13,870 | $4,544 | 32.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 55 | 55 | $13,915 | $3,356 | 24.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $3,492 | $1,332 | 38.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 16 | $4,544 | $1,330 | 29.3% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 68 | 68 | $4,760 | $1,162 | 24.4% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 46 | 46 | $4,002 | $887.02 | 22.2% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 67 | 68 | $3,400 | $755.96 | 22.2% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 59 | 59 | $7,965 | $567.93 | 7.1% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 46 | 46 | $2,392 | $480.37 | 20.1% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 20 | 20 | $1,660 | $379.78 | 22.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 18 | 18 | $1,260 | $325.89 | 25.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 18 | 18 | $900.00 | $212.76 | 23.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 461 | 769 | $218,396 | $73,765 | 33.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 224 | 462 | $102,102 | $39,714 | 38.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 157 | 163 | $70,090 | $27,342 | 39.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 173 | 183 | $43,188 | $10,124 | 23.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 57 | 57 | $20,565 | $7,339 | 35.7% |
About Robert Mohapatra, MD, MPH
Robert Mohapatra, MD, MPH is a Advanced Heart Failure and Transplant Cardiology healthcare provider based in Sewell, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2008. The National Provider Identifier (NPI) number assigned to this provider is 1336311661.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robert Mohapatra, MD, MPH has received a total of $162,137 in payments from pharmaceutical and medical device companies, with $12,532 received in 2024. These payments were reported across 1,077 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($117,708).
As a Medicare-enrolled provider, Mohapatra has provided services to 11,700 Medicare beneficiaries, totaling 15,111 services with total Medicare billing of $780,609. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Advanced Heart Failure and Transplant Cardiology
- Location Sewell, NJ
- Active Since 03/27/2008
- Last Updated 02/14/2024
- Taxonomy Code 207RA0001X
- Entity Type Individual
- NPI Number 1336311661
Products in Payments
- JARDIANCE (Drug) $67,052
- Veltassa (Drug) $51,667
- ENTRESTO (Drug) $22,519
- LifeVest (Device) $3,760
- NEXLIZET (Drug) $1,940
- ELIQUIS (Drug) $1,255
- Corlanor (Drug) $937.40
- XARELTO (Drug) $912.51
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $424.94
- Repatha (Biological) $370.34
- Optimizer (Device) $346.25
- NEXLETOL (Drug) $300.39
- BRILINTA (Drug) $287.43
- VERQUVO (Drug) $285.57
- CAMZYOS (Drug) $259.36
- Circulatory Support (Device) $255.92
- LEQVIO (Drug) $220.68
- PRADAXA (Drug) $203.15
- CardioMEMS HF System (Device) $201.38
- FARXIGA (Drug) $167.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.